1. Home
  2. KMI vs XOMAP Comparison

KMI vs XOMAP Comparison

Compare KMI & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KMI
  • XOMAP
  • Stock Information
  • Founded
  • KMI 1936
  • XOMAP N/A
  • Country
  • KMI United States
  • XOMAP United States
  • Employees
  • KMI N/A
  • XOMAP 13
  • Industry
  • KMI Natural Gas Distribution
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • Sector
  • KMI Utilities
  • XOMAP Health Care
  • Exchange
  • KMI Nasdaq
  • XOMAP Nasdaq
  • Market Cap
  • KMI N/A
  • XOMAP N/A
  • IPO Year
  • KMI 2011
  • XOMAP N/A
  • Fundamental
  • Price
  • KMI $20.19
  • XOMAP $25.90
  • Analyst Decision
  • KMI Buy
  • XOMAP
  • Analyst Count
  • KMI 8
  • XOMAP 0
  • Target Price
  • KMI $21.33
  • XOMAP N/A
  • AVG Volume (30 Days)
  • KMI 14.0M
  • XOMAP N/A
  • Earning Date
  • KMI 07-17-2024
  • XOMAP N/A
  • Dividend Yield
  • KMI 5.70%
  • XOMAP N/A
  • EPS Growth
  • KMI N/A
  • XOMAP N/A
  • EPS
  • KMI 1.09
  • XOMAP N/A
  • Revenue
  • KMI $15,288,000,000.00
  • XOMAP N/A
  • Revenue This Year
  • KMI $10.23
  • XOMAP N/A
  • Revenue Next Year
  • KMI $4.78
  • XOMAP N/A
  • P/E Ratio
  • KMI $18.52
  • XOMAP N/A
  • Revenue Growth
  • KMI N/A
  • XOMAP N/A
  • 52 Week Low
  • KMI $15.89
  • XOMAP N/A
  • 52 Week High
  • KMI $20.32
  • XOMAP N/A
  • Technical
  • Relative Strength Index (RSI)
  • KMI 63.87
  • XOMAP 57.20
  • Support Level
  • KMI $19.47
  • XOMAP $25.31
  • Resistance Level
  • KMI $20.14
  • XOMAP $25.80
  • Average True Range (ATR)
  • KMI 0.28
  • XOMAP 0.30
  • MACD
  • KMI 0.01
  • XOMAP -0.02
  • Stochastic Oscillator
  • KMI 85.21
  • XOMAP 57.08

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: